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Abstract Methyllycaconitine (MLA) is a competitive antago- 
nist of nicotinic acetylcholine receptors, with a remarkable pref- 
erence for neuronal [12sI]aBgt binding sites. We have begun to 
investigate the structural basis of its potency and subtype selectiv- 
ity. MLA is a substituted norditerpenoid alkaloid linked to a 
2-(methylsuccinimido)benzoyl moiety. Hydrolysis of the ester 
bond in MLA to produce lycoctonine diminished affinity for rat 
brain 112sI]~Bgt binding sites 2500-fold and abolished affinity for 
[3H]nicotine and muscle [t25I]aBgt binding sites. The voltage- 
gated Na ÷ channel activator aconitine, also a norditerpenoid al- 
kaloid, but with significant structural differences from lyeocton- 
ine, displayed comparable weak or absent nicotinic activity. Addi- 
tion of a 2-(methylsuccinimido)benzoyl sidechain to O-demethyl- 
ated aconitine, to mimic MLA, abolished Na ÷ channel activation 
and conferred nanomolar affinity for brain [~zsI]aBgt binding 
sites, comparable to that of MLA. We propose that the ester- 
linked 2-(methylsuccinimido)benzoyl group is necessary for nico- 
tinic potency, but ~7 selectivity resides in the norditerpenoid core 
of the molecule. 
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I. Introduction 
present in aconitine but not in MLA. Furthermore, the nordi- 
terpenoid portion of MLA is linked, via the C18 oxygen atom, 
to a 2-(methylsuccinimido)benzoyl m iety, whereas aconitine 
contains an O-methyl ether at C18 (Fig. lc). 
We have previously proposed [3] that a homocholine ester 
motif formed between the alkaloid nitrogen atom and the acyl 
group may confer nicotinic potency, by complying with the 
requirements of a proposed nicotinic pharmacophore [8]. One 
test of this hypothesis to hydrolyse the ester, producing lycoc- 
tonine (Fig. lb). This is a weak competitor at [~25I]~Bgt binding 
sites in an insect preparation [9]. A recent evaluation of a series 
of norditerpenoid alkaloids isolated from Delphinium for their 
potencies in inhibiting [125I]c~Bgt binding to rat brain and house- 
fly head membranes [4] indicated that the most potent com- 
pounds retained the 2-(methylsuccinimido)benzoyl m iety at 
C18. The potent compounds in this study were, however, sim- 
ilar to MLA with respect to substituents in the norditerpenoid 
core of the molecule. 
We have synthesised, for the first time, two anthranilate 
esters of aconitine (Fig. ld,e), in order to mimic the structure 
of MLA. We report here that addition of the full 2-(methylsuc- 
cinimido)benzoyl sidechain abolishes the ability to activate 
voltage-gated Na + channels and produces a subtype-selective 
nicotinic ligand with potency comparable to that of MLA. 
The norditerpenoid alkaloid methyllycaconitine (MLA; Fig. 
l a), which occurs naturally in Delphinium sp., is a potent com- 
petitive antagonist of nicotinic acetylcholine receptors 
(nAChR) [1]. MLA is remarkable in being highly selective for 
neuronal nAChR subtypes that are sensitive to the snake toxin 
~-bungarotoxin (c~Bgt) in both vertebrates and insects [2,3,4]. 
The nanomolar affinity with which MLA binds to, and inhibits, 
this class of nAChR [5] makes it an important probe, and we 
are interested in understanding the structural basis of its po- 
tency and selectivity. 
Aconitine (Fig. 1 c) is another norditerpenoid alkaloid, found 
in Aconitum sp. [6]. Its principal target is considered to be 
voltage-gated Na + channels, with which it interacts in such a 
way as to prevent the inactivation of the channel, thus prolong- 
ing depolarisation. Therefore, its mechanism of action is akin 
to that of batrachotoxin and veratridine [7]. Despite their sim- 
ilar trivial names, there are several structural differences 
between aconitine and MLA. These two alkaloids differ in 
oxygenation pattern, stereochemistry, and the presence of 
bulky functional groups, such as benzoyl and acetyl, which are 
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2. Materials and methods 
2.1. Chemistry 
MLA was hydrolysed tolycoctonine in77% yield by base-catalysed 
hydrolysis (2 N KOH in ethanol, 25 h at 20°C; purified by silica gel 
chromatography using dichloromethane/methanol/NH4OH 100:10:1 
as eluant). The detailed chemistry for the O-demethylation and anthra- 
noylation of aconitine, to give 3-deoxy-18-O-desmethyl(2-amino-ben- 
zoyl)aconitine (Fig. ld) and 3-deoxy-18-O-desmethyl[2-(methylsuccin- 
imido)benzoyl]-aconitine (Fig. 1 e), has been reported elsewhere [10,11]. 
2.2. Nicotinic binding assays 
Competitive binding assays were carried out as previously described 
for neuronal nAChR labelled with [~25I]c~Bgt or [3H]nicotine in rat brain 
membranes [2] and for muscle nAChR labelled with [t25I]~Bgt in rat 
muscle xtract [12]. IC50 values were determined bycurve fitting the Hill 
equation to the data; K~ values were derived from IC50 values according 
to the Cheng and Prusoff equation [13]. 
2.3. Indirect assays of Na ÷ channel activation 
The tetrodotoxin-sensitive stimulation of [3H]dopamine release from 
brain slices by Na ÷ channel activators was employed to evaluate the 
interaction of norditerpenoid alkaloids with this voltage-sensitive ion 
channel. Tissue slices (0.2 mm) were prepared from rat frontal cortex 
and loaded with [3H]dopamine (0.1 ¢tM; 45 Ci/mmol) in Krebs Ringer 
containing 80/tM pargyline and 1.1 mM ascorbic acid, for 25 min at 
37°C. Aliquots (200 pl; ~ 15 mg tissue) were incubated with drug, in the 
presence and absence of tetrodotoxin (TTX; 10 ¢tM), for 15 min at 
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37°C, followed by dilution with cold buffer and brief centrifugation. 
Radioactivity released into the medium above basal release was taken 
as an index of Na ÷ channel activation. Release was calculated as % of 
total radioactivity in the tissue at time zero. 
2.4. Materials 
~Bgt, veratridine and TTX were purchased from the Sigma Chemical 
Co. (Poole, Dorset, UK). c~Bgt was iodinated to a specific activity of 
700 /zCi/mmol. [3H]Dopamine was purchased from Amersham Int. 
(Amersham, Bucks., UK). Aconitine was purchased from Aldrich 
Chemical Co. MLA was purified from a Garden Hybrid Delphinium 
strain as previously described [14]. Potential ligands were dissolved in 
ethanol to a stock concentration of 10-3M and stored at 4°C. 
3. Results 
Lycoctonine was prepared by base-catalysed hydrolysis of 
MLA. In order to facilitate the esterification faconitine, itwas 
first necessary to deoxygenate atC3 and O-demethylate at C18 
to give 3-deoxy-18-O-desmethylaconitine [10]. Subsequently, 
anthranoyl and 2-(methylsuccinimido)benzoyl groups were 
added [11]: the products are 3-deoxyaconitine based analogues 
of MLA. The 2-(methylsuccinimido)benzoyl aconitine (Fig. le) 
was homogeneous by thin layer chromatography (TLC), and 
gave satisfactory mass, 13C and ~H NMR spectra. The anthra- 
noyl aconitine (Fig. ld) gave a satisfactory ~H NMR spectrum, 
but contained trace impurities as judged by TLC (SiO2, 10% 
methanol/dichloromethane). Importantly, Aeonitum sp. which 
are the source of aconitine, do not contain MLA, ruling it out 
as a potential contaminant. 
These semi-synthetic products, together with the parent corn- 
pounds aconitine and MLA, were assayed for nicotinic potency 
in competition binding assays for both muscle and neuronal 
nAChR. [1251]~Bgt and [3H]nicotine binding define the two 
major subtypes of nAChR found in mammalian brain. The 
inhibition curves are depicted in Fig. 2 and K~ values are given 
in Table 1. MLA, isolated and purified in this laboratory as the 
free base [14], inhibited [125I]~Bgt binding to rat brain mem- 
branes with a K, of 4 nM, and was at least 3 orders of magnitude 
less potent at [3H]nicotine binding sites or muscle nAChR. 
These data are in good agreement with our previous evalua- 
tions of MLA [2,3]. In contrast, aconitine (Fig. lc) was only a 
weak competitor at neuronal [~25I]~Bgt binding sites (Ki = 19 
pM) and had no appreciable activity at any of the other nAChR 
subtypes examined. The norditerpenoid alkaloid lycoctonine 
(Fig. lb) showed a similar binding profile (K~ = 10 pM at 
[~25I]~Bgt binding sites) and was a feeble competitor compared 
with MLA. 
Addition of 2-aminobenzoyl and 2-(methylsuccin- 
imido)benzoyl groups to 3-deoxy-18-O-desmethylaconitine 
progressively enhanced nicotinic potency at brain [~25I]~Bgt 
sites, with Ki values of 0.3/zM and 6 nM, respectively, com- 
pared with 4 nM for MLA. At neuronal [3H]nicotine and mus- 
cle [125I]~Bgt binding sites only the 2-(methylsuccin- 
imido)benzoyl-analogue displayed any potency, inhibiting 
[~25I]~Bgt binding to muscle with a Ki of 42 pM. 
In an indirect assay of Na ÷ channel activation, based on the 
TTX-sensitive stimulation of [3H]dopamine r lease from fron- 
tal cortex slices, aconitine produced a concentration-dependent 
release of radiolabel, with an ECs0 of 21.2 _+ 1.2 pM (Fig. 3a). 
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Fig. 1. Chemical structures of (a) MLA, (b) lycoctonine, (c) aconitine, (d) 3-deoxy-18-O-desmethyl(2-aminobenzoyl)aconitine; (e) 3-deoxy-18-O- 
desmethyl[2-(methyl-succinimido)benzoyl]aconitin e. 
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Fig. 2. Competition binding assays for (a) [t25I]c~Bgt binding sites in rat brain membranes; (b) [3H]nicotine binding sites in rat brain membranes; 
(c) [~25I]~Bgt binding sites in rat muscle xtract. Binding assays were carried out as described in section 2. Each point is the mean of 3 independent 
assays, vertical bars indicate the S.E.M. (o) MLA; (•) lycoctonine; (e) aconitine; (I) 3-deoxy-18-O-desmethyl(2-aminobenzoyl)aconitine; (v) 3-deoxy- 
18- O-desmethyl[2-(methylsuccinimido)-benzoyl]aconitin e. 
It was less efficacious and less potent han veratridine, which 
gave an ECs0 of 3.1 +_ 0.3 ktM. The effects of both drugs were 
abolished by coincubation with TTX. In contrast, MLA, lycoc- 
tonine and 2-(methylsuccinimido)benzoyl aconitine had no ef- 
fect on [3H]dopamine r lease (Fig. 3b). 
4. Discussion 
MLA is a potent nicotinic ligand with selectivity for neuronal 
~Bgt-sensitive nAChR. Hydrolysis of the C18 ester bond to 
produce lycoctonine resulted in a 2500-fold reduction in po- 
tency. This agrees with the differential potencies of MLA and 
lycoctonine in inhibiting []25I]~Bgt binding to fly head homoge- 
nate, although this insect nAChR may be even more sensitive 
to MLA than its counterpart in rat brain [9]. Lycoctonine was 
without activity at brain [3H]nicotine binding sites, and has 
been reported to be devoid of neuromuscular blocking activity 
in the rat phrenic nerve~liaphragm preparation [15]. Lycocton- 
ine did not evoke the release of [3H]dopamine, suggesting that 
the structural differences between this alkaloid and aconitine 
were sufficient o render lycoctonine incapable of activating 
voltage-gated Na ÷ channels. 
Aconitine was comparable to lycoctonine in its weak nico- 
tinic activity. Aconitine inhibits [~:5I]c~Bgt binding to fly head 
homogenate with a K~ of 270/,tM [9], although it has been 
reported to be more potent in depressing a rat neuromuscular 
response [15]. Given its actions at voltage-gated Na + channels, 
it is not clear that this neuromuscular depression reflects an 
interaction with nAChR [16]. However, the generation of nano- 
molar affinity for rat brain [~25I]~Bgt binding sites, comparable 
to that of MLA, by addition of a 2-(methylsuccinimido)benzoyl 
moiety is a striking indication that this esterification is respon- 
sible for nicotinic potency. This result is the first demonstration 
that significant changes can be made to the norditerpenoid core 
of the ligand without loss of activity, providing the 2-(meth- 
ylsuccinimido)benzoyl moiety is present. The anthranoyl inter- 
mediate (lacking the methylsuccinyl ring) had lower activity, 
and we propose, therefore, that the ester bond alone is insuffi- 
Table 1 
Binding affinities of MLA, aconitine and related structures at nAChR 
Brain [~25I]~Bgt Brain [3H]nicotine Muscle [tzsI]~Bgt 
Ki (M)* 
MLA 
Lycoctonine 
Aconitine 
3-Deoxy- 18- O-desmethyl(2-aminobenzoyl)aconitine 
3 -Deoxy- 18- O-desmethyl[2-(methylsuccinimido)-benzoyl]aconitine 
4.3±1.5×10 -9 7.5±1.5×10 -6 3.0±1.1×10 -6 
1.0±0.1×10 -5 >1×10 4 n.d, 
1.9±0.4×10 5 >1×10 -4 >1×10 -4 
3.1±0.7×10 7 >1×10 -4 > lx l0  -4 
6.0±1.5×10 -9 >1×10 -4 4.2±0.5×10 -5 
*Mean + S.E.M. from 3 independent assays. 
n.d. = not determined. 
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Fig. 3. Stimulation of [3H]dopamine r lease from rat cortical slices by 
activation of TTX-sensitive Na ÷ channels. (a) Concentration depend- 
ence of veratridine ( ) and aconitine (A) stimulated [3H]dopamine r - 
lease. Cortical slices were loaded with [3H]dopamine and incubated with 
increasing concentrations of drug for 15 min. [3H]Dopamine r leased 
into the medium was measured and corrected for basal release, deter- 
mined in the presence of TTX. Values are the mean + range from 
2 independent assays. (b) Comparison of norditerpenoid alkaloids. 
MLA (500 pM), lycoctonine (LYC; 400 /IM) and 3-deoxy-18-O- 
des-methyl[2-(methylsuccinimido)benzoyl]aconitine (MSBA; 150/~M) 
were compared with a maximally effective concentration f aconitine 
(Acon; 100/tM) for their ability to evoke [3H]dopamine r lease from 
cortical slices. TTX sensitivity was demonstrated bycoincubation of
aconitine (100 ILM) with 10/zM TTX (Acon+TTX). Values are pre- 
sented as a % of the response to aconitine, determined inparallel, and 
are the mean + range or S.E.M. of the number of independent assays 
indicated. 
cient for full potency. This is in accord with the preference 
shown for the succinimide substituent in the series of norditer- 
penoid alkaloids imilar to MLA, published recently by Kukel 
and Jennings [4]. 
Comparison of activities at the three nAChR sites assayed 
in the present study shows that the preference for neuronal 
[~25I]~Bgt binding sites is conserved across the series of com- 
pounds examined. This preference is evident even in aconitine 
and lycoctonine, which share a common orditerpenoid carbon 
core, although they differ in several functional groups. From 
the binding data, we propose that the rigid norditerpenoid ring 
structure is the most important determinant of ~7 selectivity. 
However, the substituents probably influence activity at 
[3H]nicotine binding sites, as the 2-(methylsuccinimido)benzoyl 
derivative of aconitine shows more subtype-selectivity than 
MLA. Moreover, such differences must explain the failure of 
lycoctonine to activate TTX-sensitive Na + channels, in contrast 
to aconitine. The addition of the 2-(methylsuccinimido)benzoyl 
group to aconitine abolished its ability to stimulate TTX-sensi- 
tive [3H]dopamine release, demonstrating that the pharmaco- 
phores for the two sites (voltage-gated Na + channel and 
nAChR) have little overlap. 
This study defines the norditerpenoid core of MLA as the 
major determinant of ~t7 nAChR selectivity, and establishes the 
prime importance of the 2-(methylsuccinimido)benzoyl substit- 
uent for nicotinic potency. The conversion of aconitine to a 
potent nicotinic ligand, comparable to MLA, with concomitant 
loss of TTX-sensitive Na ÷ channel activation, by addition of a 
2-(methylsuccinimido)benzoyl sidechain is a major step to- 
wards the rational design of nicotinic subtype-selective drugs. 
Acknowledgements." We thank the Wellcome Trust (Project Grant 
036214) and EC for financial support. B.V.L.P. is a Lister Institute 
Research Professor. 
References  
[1] Wonnacott, S., Albuquerque, E.X. and Bertrand, D. (1993) in: 
Methods in Neurosciences, vol 12 (Conn, M.ed.) pp. 263-275, 
Academic Press, New York. 
[2] MacAllan, D.R.E., Lunt, G.G., Wonnacott, S., Swanson, K.L., 
Rapoport, H. and Albuquerque, E.X. (1988) FEBS Lett. 226, 
357-363. 
[3] Ward, J.M., Cockcroft, V.B., Lunt, G.G., Smillie, F.S. and 
Wonnacott, S. (1990) FEBS Lett. 270, 4548. 
[4] Kukel, C.F and Jennings, K.R. (1994) Can. J. Physiol. Pharmacol. 
72, 104-107. 
[5] Alkondon, M., Pereira, E.ER., Wonnacott, S.and Albuquerque, 
E.X. (1992) Mol. Pharmacol. 41,802-808. 
[6] Benn, M.H. and Jacyno, J.M. (1983) in: Alkaloids: Chemical and 
Biological Perspectives, vol. 1 (Pelletier, S.W. ed.) Wiley, New 
York. 
[7] Catterall, W.A. (1980)Annu. Rev. Pharmacol. Toxicol. 20, 15~,3. 
[8] Sheridan, R.P., Nilakantan, R., Dixon, J.S. and Venkataraghavan, 
R. (1986) J. Med. Chem. 29, 899-906. 
[9] Jennings, K.R., Brown, D.G. and Wright, D.P. (1986) Experientia 
42, 611-613. 
[10] Blagbrough, I.S., Hardick, D.J., Wonnacott, S.and Potter, B.V.L. 
(1994) Lett. 35, 3367 3370. 
[11] Hardick, D.J., Blagbrough, I.S., Wonnacott, S.and Potter, B.V.L. 
(1994) Tetrahedron Lett. 35, 3371-3374. 
[12] Garcha, H.S., Thomas, P., Spivak, C.E., Wonnacott, S. and 
Stolerman, I.P (1993) Psychopharmacology l l0, 347-354. 
[13] Cheng, Y.-C. and Prusoff, W.H. (1973) Biochem. Pharmacol. 22, 
3099-3108. 
[14] Coates, P.A., Blagbrough, I.S., Hardick, D.J., Rowan, M.G., 
Wonnacott, S. and Potter, B.V.L. (1994) Tetrahedron Lett. 35, 
8701-8704. 
[15] Nambi Aiyar, V., Benn, M.H., Hanna, T., Jacyno, J., Roth, S.H. 
and Wilkens, J.L. (1979) Experientia 35, 1367-1368. 
[16] Muroi, M., Kimura, I. and Kimura, M. (1990) Neuropharmacol- 
ogy 29, 567 572. 
